Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, United States.
Bioorg Med Chem. 2010 Apr 1;18(7):2756-66. doi: 10.1016/j.bmc.2010.02.013. Epub 2010 Feb 11.
Malaria is endemic in tropical and subtropical regions of Africa, Asia, and the Americas. The increasing prevalence of multi-drug-resistant Plasmodium falciparum drives the ongoing need for the development of new antimalarial drugs. In this light, novel scaffolds to which the parasite has not been exposed are of particular interest. Recently, workers at the Swiss Tropical Institute discovered two novel 4-oxo-3-carboxyl quinolones active against the intra-erythrocytic stages of P. falciparum while carrying out rationally directed low-throughput screening of potential antimalarial agents as part of an effort directed by the World Health Organization. Here we report the design, synthesis, and preliminary pharmacologic characterization of a series of analogues of 4-oxo-3-carboxyl quinolones. These studies indicate that the series has good potential for preclinical development.
疟疾在非洲、亚洲和美洲的热带和亚热带地区流行。抗药性疟原虫日益普遍,这促使人们不断需要开发新的抗疟药物。在这方面,寄生虫尚未接触过的新型支架特别受到关注。最近,瑞士热带研究所的工作人员在进行世界卫生组织指导的有针对性的努力的一部分,进行合理定向的低通量筛选潜在抗疟药物时,发现了两种新型的 4-氧代-3-羧基喹啉酮,对疟原虫的红细胞内阶段具有活性。在这里,我们报告了一系列 4-氧代-3-羧基喹啉酮类似物的设计、合成和初步药理特性。这些研究表明,该系列具有很好的临床前开发潜力。